Rejection of the second allogeneic graft in a patient with severe aplastic anemia reversed by antilymphocyte globulin and donor lymphocyte infusions

P Ljungman; M Lawler; B Lönnqvist; O Ringdén; A Shanwell

Rejection of the second allogeneic graft in a patient with severe aplastic anemia reversed by antilymphocyte globulin and donor lymphocyte infusions

Bone Marrow Transplant. 1996 Dec;18(6):1179-81.

Authors

P Ljungman¹, M Lawler, B Lönnqvist, O Ringdén, A Shanwell

Affiliation

¹ Department of Medicine, Huddinge University Hospital, Karolinska Institute, Sweden.

PMID: 8971392

Abstract

Rejection after allogeneic BMT for aplastic anemia is a complication with a high risk of mortality. We describe a patient who, following a second episode of rejection after a second BMT entered a third durable remission subsequent to treatment with ALG, donor lymphocyte infusions, GM-CSF, and erythropoietin. Therapy was well tolerated. At 5 years after rejection treatment, his hematopoiesis is of complete donor origin as determined by analyses of short tandem repeats. Thus, donor lymphocyte infusions can be considered as a therapy option for marrow rejection after allogeneic BMT for aplastic anemia.

Publication types

Case Reports

MeSH terms

Adult
Anemia, Aplastic / therapy*
Antilymphocyte Serum / therapeutic use*
Bone Marrow Transplantation* / immunology
Cyclosporine / therapeutic use
Erythropoietin / therapeutic use
Graft Rejection / therapy*
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
Humans
Immunosuppression Therapy
Immunosuppressive Agents / therapeutic use
Lymphocyte Transfusion*
Male
Microsatellite Repeats
Polymerase Chain Reaction
Remission Induction
Transplantation, Homologous

Substances

Antilymphocyte Serum
Immunosuppressive Agents
Erythropoietin
Granulocyte-Macrophage Colony-Stimulating Factor
Cyclosporine